Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03785249 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion moved earlier from Dec 31, 2026 to Jun 23, 2026v40
  2. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 822 to confirmed 731 · Study sites: 228 to 222v39 Show 2 more changesShow less
    • Enrollment target: estimated 822 to confirmed 731
    • Study sites: 228 to 222
  3. Primary completion date: Jul 14, 2025 to Dec 31, 2026 Completion date: Jan 16, 2026 to Dec 31, 2026 · Site contacts updated at 1 of 228 sitesv38 Show 2 more changesShow less
    • Completion date: Jan 16, 2026 to Dec 31, 2026
    • Site contacts updated at 1 of 228 sites
  4. Study sites: 214 to 228v37
  5. Study sites: 107 to 214 Primary completion date: Jul 31, 2025 to Jul 14, 2025 · Completion date: Jan 31, 2026 to Jan 16, 2026 · Start date: Dec 26, 2018 to Jan 15, 2019v36 Show 3 more changesShow less
    • Primary completion date: Jul 31, 2025 to Jul 14, 2025
    • Completion date: Jan 31, 2026 to Jan 16, 2026
    • Start date: Dec 26, 2018 to Jan 15, 2019
Show 34 earlier versionsHide 34 earlier versions
  1. Study sites: 98 to 107 Primary completion date: Jul 2025 to Jul 31, 2025 · Completion date: Jan 2026 to Jan 31, 2026v35 Show 2 more changesShow less
    • Primary completion date: Jul 2025 to Jul 31, 2025
    • Completion date: Jan 2026 to Jan 31, 2026
  2. Re-verified, no change to tracked fieldsv34
  3. Primary completion date: Dec 2023 to Jul 2025 Completion date: Sep 2024 to Jan 2026 · Start date: Jan 15, 2019 to Dec 26, 2018v33 Show 2 more changesShow less
    • Completion date: Sep 2024 to Jan 2026
    • Start date: Jan 15, 2019 to Dec 26, 2018
  4. Study sites revised (98)v32 See this version in full on ClinicalTrials.gov ↗
  5. Primary completion date: Dec 2022 to Dec 2023 Enrollment target: 740 to 822 · Study sites: 81 to 98 · Completion date: Sep 2023 to Sep 2024v31 Show 3 more changesShow less
    • Enrollment target: 740 to 822
    • Study sites: 81 to 98
    • Completion date: Sep 2023 to Sep 2024
  6. Primary completion date: Mar 2022 to Dec 2022 Enrollment target: 565 to 740 · Study sites: 75 to 81 · Completion date: Dec 2022 to Sep 2023 · 1 morev30 Show 4 more changesShow less
    • Enrollment target: 565 to 740
    • Study sites: 75 to 81
    • Completion date: Dec 2022 to Sep 2023
    • Study arms: 6 to 9
  7. Eligibility criteria expanded, about 7 wordsv29 See this version in full on ClinicalTrials.gov ↗
  8. Enrollment target: 391 to 565 Study sites: 69 to 75 · Primary completion date: Dec 2021 to Mar 2022 · Completion date: Sep 2022 to Dec 2022 · 1 morev28 Show 4 more changesShow less
    • Study sites: 69 to 75
    • Primary completion date: Dec 2021 to Mar 2022
    • Completion date: Sep 2022 to Dec 2022
    • Study description expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  9. Study sites: 68 to 69v27
  10. Study sites: 65 to 68v26
  11. Primary completion date: Dec 2020 to Dec 2021 Completion date: Sep 2021 to Sep 2022v25 Show 1 more changeShow less
    • Completion date: Sep 2021 to Sep 2022
  12. Study sites: 63 to 65v24
  13. Study sites: 56 to 63v23
  14. Study sites: 47 to 56v22
  15. Study sites: 43 to 47v21
  16. Study sites: 41 to 43v20
  17. Study sites: 40 to 41v19
  18. Study sites: 39 to 40v18
  19. Study sites: 35 to 39v17
  20. Study sites: 34 to 35v16
  21. Study sites: 28 to 34v15
  22. Study sites: 27 to 28v14
  23. Eligibility criteria shortened, about 3 wordsv13 See this version in full on ClinicalTrials.gov ↗
  24. Study sites: 25 to 27v12
  25. Enrollment target: 200 to 391 Primary completion date: Apr 2020 to Dec 2020 · Primary endpoints: 2 to 3 · Study sites: 22 to 25 · 5 morev11 Show 8 more changesShow less
    • Primary completion date: Apr 2020 to Dec 2020
    • Primary endpoints: 2 to 3
    • Study sites: 22 to 25
    • Completion date: Apr 2020 to Sep 2021
    • Interventions: MRTX849 (Drug) to Afatinib (Drug), Cetuximab (Drug), MRTX849 (Drug), Pembrolizumab (Drug)
    • Secondary endpoints: 2 to 4
    • Study arms: 3 to 6
    • Study title expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  26. Study sites: 13 to 22v10
  27. Re-verified, no change to tracked fieldsv9
  28. Study sites: 12 to 13v8
  29. Study sites: 11 to 12 Study description expanded, about 3 words · Study title expanded, about 4 wordsv7 Show 2 more changesShow less
    • Study description expanded, about 3 words
    • Study title expanded, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  30. Study sites: 9 to 11v6
  31. Study sites: 6 to 9v5
  32. Study sites: 3 to 6v4
  33. Study sites: 2 to 3 Start date changed from estimate of Jan 2019 to Jan 15, 2019v3 Show 1 more changeShow less
    • Start date changed from estimate of Jan 2019 to Jan 15, 2019
  34. Study sites: 1 to 2v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.
Trial Details
NCT Number NCT03785249
Lead Sponsor Mirati Therapeutics Inc.
Conditions Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Enrollment 731 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov